Radioligand Therapy Market to Reach US$15.80B by 2033 at 21.9% CAGR | Targeted Cancer Therapies Transform Radioligand Market Landscape

Radioligand Therapy Market Size and Forecast

Radioligand Therapy Market reached US$ 2.41 billion in 2024 and is expected to reach US$ 15.80 billion by 2033, growing at a CAGR of 21.9% during the forecast period 2025-2033.

DataM Intelligence has published a new research report on "Radioligand Therapy Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/radioligand-therapy-market?rk

Recent Developments:
✅ October 2025: Novartis announced expanded global manufacturing capacity for radioligand therapies to support increasing demand for prostate and neuroendocrine tumor treatments. The investment strengthens isotope production, supply chain resilience, and distribution networks, ensuring broader patient access to targeted radiopharmaceutical therapies.

✅ September 2025: Eli Lilly and Company advanced its oncology pipeline by accelerating clinical trials of next-generation radioligand candidates targeting solid tumors. The company is focusing on precision oncology approaches that combine diagnostic imaging with targeted radioactive payloads to improve therapeutic outcomes.

✅ August 2025: Bayer AG expanded research collaborations aimed at developing novel alpha-emitting radioligand therapies. These therapies are designed to deliver high-energy radiation directly to cancer cells while minimizing damage to surrounding healthy tissues, enhancing safety and efficacy profiles.

✅ June 2025: POINT Biopharma Global Inc. reported positive Phase II clinical data for a prostate cancer-focused radioligand therapy candidate. The results demonstrated improved progression-free survival rates, reinforcing growing confidence in targeted radiopharmaceutical platforms for advanced oncology treatment.

Mergers & Acquisitions:
✅ November 2025: Novartis completed the acquisition of a specialized radiopharmaceutical manufacturing facility in North America to scale production of lutetium-based therapies, strengthening its leadership in the radioligand therapy segment.

✅ October 2025: Bristol Myers Squibb acquired a clinical-stage biotech focused on targeted radioligand oncology assets, expanding its precision medicine portfolio and reinforcing its position in next-generation cancer therapeutics.

✅ July 2025: AstraZeneca entered into a strategic acquisition of a radiopharmaceutical development startup to integrate radioligand therapies with its antibody-drug conjugate (ADC) pipeline, aiming to create combination oncology regimens.

✅ May 2025: Telix Pharmaceuticals acquired a molecular imaging company to enhance its theranostics capabilities, enabling integrated diagnostic and therapeutic solutions within the rapidly expanding radioligand therapy market.

Key Players:

Eli Lilly and Company., Lantheus, Curium, AstraZeneca, ITM Isotope Technologies Munich SE, Telix Pharmaceuticals Limited, Oranomed, Sanofi, RadioMedix, Inc., Clarity Pharmaceuticals, Ariceum Therapeutics, Blue Earth Therapeutics, Novartis AG and Bayer AG.

Growth Forecast Projected:

The Global Radioligand Therapy Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Radioligand Therapy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=radioligand-therapy-market?rk

Key Segments:

By Type
The market is segmented into Lutetium Lu-177 60%, Radium Ra 223 Dichloride 30%, and Others 10%, with Lutetium Lu-177 dominating due to its increasing adoption in targeted cancer therapy, particularly in prostate cancer and neuroendocrine tumors. Its favorable safety profile and targeted radiation delivery enhance therapeutic outcomes. Radium Ra 223 Dichloride holds a significant share due to its proven effectiveness in treating metastatic castration-resistant prostate cancer with bone metastases. Ongoing clinical trials exploring novel isotopes contribute to the growth of the "others" segment.

By Target
By target, the market includes Prostate-Specific Membrane Antigen (PSMA) 65% and Somatostatin Receptor (SSTR) 35%, with PSMA-targeted therapies leading due to rising incidence of prostate cancer and strong clinical success of PSMA-targeting radioligands. Somatostatin receptor-targeted therapies hold a substantial share driven by their application in treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Advancements in precision oncology and companion diagnostics are accelerating growth across both targets.

By Application
The market is segmented into Prostate Cancer 55%, Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) 35%, and Others 10%, with prostate cancer dominating due to increasing prevalence globally and growing regulatory approvals for PSMA-targeted therapies. GEP-NETs represent a significant share supported by established somatostatin receptor-based radioligand treatments. Expansion of clinical research into additional solid tumors supports future segment diversification.

Regional Analysis
North America - 40% Share
North America leads with 40% share due to advanced nuclear medicine infrastructure, strong regulatory approvals, and high adoption of targeted oncology therapies. The U.S. is the primary contributor, supported by increasing prostate cancer diagnosis rates and reimbursement coverage for radioligand treatments.

Europe - 30% Share
Europe accounts for 30% share, driven by strong nuclear medicine expertise, early clinical adoption, and supportive healthcare systems in Germany, France, and the UK. Expanding research collaborations further boost market growth.

Asia Pacific - 18% Share
Asia-Pacific holds 18% share driven by rising cancer incidence, improving healthcare infrastructure, and increasing investments in nuclear medicine capabilities in China, Japan, and India.

Latin America - 7% Share
Latin America captures 7% share, supported by gradual adoption of advanced oncology treatments and improving access to specialized cancer care in Brazil and Mexico.

Middle East & Africa - 5% Share
The Middle East & Africa region holds 5% share, driven by expanding tertiary care hospitals and increasing oncology treatment capabilities in GCC countries and South Africa.

Benefits of the Report:

Chapter 1: Lays the foundation by defining the scope of the report, highlighting core market segments across regions, product types, and applications. It delivers a clear snapshot of current market size, growth potential, and how the industry is expected to evolve in both the near and long term.

Chapter 2: Spotlights the most impactful market insights, unveiling the transformative trends and forces shaping the future of the industry.

Chapter 3: Provides a deep dive into the competitive landscape of , covering revenue shares, strategic initiatives, and notable mergers & acquisitions that are reshaping the market.

Chapter 4: Presents detailed company profiles of leading players featuring financial performance, product portfolios, profit margins, and key milestones that set them apart in the industry.

Chapters 5 & 6: Break down revenue analysis at both regional and country levels, offering precise data on market size, growth drivers, and expansion opportunities across global markets.

Chapter 7: Analyzes the market by product type, spotlighting segment-specific opportunities and helping stakeholders identify untapped, high-growth areas.

Chapter 8 :Explores the market through application-based segmentation, assessing demand across industries and pinpointing downstream sectors with the strongest potential for growth.

Chapter 9: Maps the industry's supply chain in detail, tracing upstream and downstream activities to provide clarity on value creation across the ecosystem.

Chapter 10: Wraps up with a concise summary of the report's key insights distilling the most critical findings and strategic takeaways for decision-makers and stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/radioligand-therapy-market?rk

FAQ

Q1: What is the current size of the Radioligand Therapy Market?

A: The Radioligand Therapy Market reached US$ 2.41 billion in 2024 and is expected to reach US$ 15.80 billion by 2033

Q2: How rapidly will the Market expand?

A: The Radioligand Therapy market is projected to grow at a CAGR of 21.9% between 2025 and 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?rk

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?rk

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.